Forget apples — doctors find eating this fruit daily can lower depression risk by 20%
But not everyone realizes that having a happy belly also has a major impact on your mood since about 90% of your body's serotonin and over 50% of your dopamine — two crucial neurotransmitters responsible for making you feel good — are produced in your gut.
For this reason, scientists often call the gut 'the second brain.'
And while an apple a day may keep the doctor away, research shows an orange a day might keep the blues at bay.
Dr. Raaj Mehta, a physician and instructor at Harvard Medical School, and his colleagues analyzed the data of over 30,000 women and found that those who consumed a lot of citrus were much less likely to develop depression than those who didn't.
Their findings were published late last year in the journal Microbiome.
'We found that eating one medium orange a day may lower the risk of developing depression by about 20%,' Mehta told the Harvard Gazette last month.
'And the effect seems to be specific to citrus. When we look at people's total fruit or vegetable consumption, or at other individual fruits such as apples or bananas, we don't see any relationship between intake and risk of depression.'
Using stool samples, researchers discovered eating more citrus was associated with increased levels of a beneficial gut bacterium called Faecalibacterium prausnitzii (F. prausnitzii), which is known for its anti-inflammatory properties but might also help serotonin and dopamine make their way to the brain.
A study published in 2022 found that eating fewer citrus fruits was clearly associated with a heightened risk of depression in patients with chronic health failure.
However, Mehta noted that it's 'hard to compare the effectiveness of citrus to traditional antidepressants…because we're talking about preventingdepression, and those drugs are usually used to treatdepression once a person is already experiencing it.'
The researchers also acknowledged that their study had certain limitations, as most of the participants were white, middle-aged women; additionally, while they controlled for several factors, there's still the possibility that their findings were correlational rather than causal.
Still, eating an orange — or lemon or grapefruit, if that's what you prefer — a day certainly can't hurt, and the study sheds light on the relationship between the gut and the brain, as well as the role these fruits play on it.
'I hope our results inspire other researchers to look into the link between diet and mental health,' Mehta said. 'I think people know intuitively that the foods we eat impact our mood. We even have a term for this: comfort foods, which make ourselves feel better in the short term.'
'There's such a huge unmet need for depression treatments, and eating citrus doesn't really have any major side effects,' he added, 'so it would be great to see how much this simple treatment can help.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
3 hours ago
- Fox News
Why 'fibermaxxing' could help prevent disease, according to a top expert
Dr. Timothy Spector, a leading microbiome researcher and scientific co-founder of ZOE, shares why he's on board with "fibermaxxing,' the nutrition trend that helps to improve gut health and improve digestion.
Yahoo
a day ago
- Yahoo
Microbiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
CAMBRIDGE, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial has recruited 29 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial results are expected by the end of 2025. The COMPOSER-1 study is designed to investigate the safety, tolerability, and initial signals of efficacy of MB310 in a randomised, placebo-controlled, double-blind, clinical trial. The degree to which the bacteria within MB310 successfully engraft into patients' intestinal microbial community is also being measured. The study has recruited patients with active, mild-to-moderate UC, who are taking two capsules of MB310 (active or matched placebo) once a day for 12 weeks in addition to their standard of care medication, with a 12-week follow-up period. (Study identifiers: NCT06582264; 2023-507376-50). Ulcerative colitis, an inflammatory bowel disease, is a debilitating disease that affects over 1.4 million people globally. MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains with the potential to deliver long-term remission to UC patients, without immunosuppression or unwanted side-effects. The bacterial strains in MB310 were identified by analysing clinical and microbiome data from a faecal microbiota transplant (FMT) study in UC patients, carried out with collaborators at the University of Adelaide. The results demonstrated the ability of a microbiome therapy to induce remission in UC without significant side-effects. Microbiotica's analysis identified the engrafting bacteria were associated with clinical response, leading to the development of MB310 as an LBP. Preclinical studies have demonstrated that MB310 acts via at least three independent mechanisms that are central to the pathology of UC: promoting the healing of the damaged gut epithelial barrier, regulating the balance of cytokines that are inflammatory (TNF) and immune-modulatory (IL-10); and inducing a regulatory T-cell response. Dr Robert Tansley, Microbiotica's Chief Medical Officer, said, 'We are delighted that enrolment into the trial has proceeded to plan and that the trial is now fully recruited. We thank our investigational sites and the patients for their participation, and eagerly await the results of the study. There is a considerable body of evidence that FMT is beneficial for mild-to-moderate UC patients, and we believe our microbiome approach based on specific bacteria could provide a precision microbiome-based treatment for this debilitating disease.' Notes to Editors About Ulcerative Colitis - MB310 and the COMPOSER-1 study Ulcerative colitis, an inflammatory bowel disease, is a debilitating disease that affects over 1.4 million people globally. MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC patients, without immunosuppression or unwanted side-effects. The bacterial strains in MB310 were identified by analysing clinical and microbiome data from a faecal microbiota transplant (FMT) study in UC patients carried out with collaborators at the University of Adelaide. The results demonstrated the ability of a microbiome therapy to induce remission in UC without significant side-effects. Microbiotica's analysis identified the engrafting bacteria associated with clinical response, leading to the development of MB310 as an LBP. Microbiotica announced the start of its first clinical trial with MB310 in November 2024, the COMPOSER-1 study. The study is investigating the safety, tolerability, and initial signals of efficacy of MB310 in a randomised, placebo-controlled, double-blind, clinical trial. The degree to which the bacteria within MB310 successfully engraft into patients' intestinal microbial community will be measured. The study is now fully recruited having enrolled 29 patients with active, mild-to-moderate UC, who will take two capsules of study medication (active or matched placebo) once a day for 12 weeks in addition to their standard of care medication, with a 12-week follow-up period. (Study identifiers: NCT06582264; 2023-507376-50) . Data readout is expected by the end of 2025. About Microbiotica Microbiotica is a private, clinical-stage, biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. The Company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The Company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development. The Company is creating a novel pipeline of programmes in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis). It has a major partnership with Cancer Research UK and Cambridge University Hospitals in immuno-oncology. The Company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-PD-1 immunotherapy. MB310 was developed in collaboration with the University of Adelaide. Both programmes have data read-outs in 2025. Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK. Microbiotica has raised more than £62 million equity investment, including a £50 million Series B in 2022, with venture investors including British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The Company has also received financial support from the US-based Crohn's and Colitis Foundation. For more information, please visit and follow us on LinkedIn. Media contacts Microbiotica Ro Gardner, rgardner@ +44 7801 480569 Scius Communications Sue Charles, sue@ +44 7968 726585 Daniel Gooch, daniel@ +44 7747 875479
Yahoo
4 days ago
- Yahoo
What is Lyme disease, and does Justin Timberlake have it?
Justin Timberlake isn't the only person to recently contract tick-borne Lyme disease. New Jersey had the third-most cases of Lyme disease in the nation as recently as 2022, according to the New Jersey Department of Health. And with Lyme disease outbreaks on the rise throughout the country, here's what you need to know about Lyme disease and steps you can take to protect yourself and your family. What is Lyme disease? Lyme disease is caused by tick bites but isn't spread person-to-person, noted the the New Jersey Department of Health. The Lyme disease-causing ticks thrive in woodsy areas, such as much of New Jersey. What are Lyme disease symptoms? The three stages of Lyme disease have different symptoms, according to PennMedicine: Stage 1: chills; fevers; joint and muscle pain Stage 2: Nerve numbness; facial paralysis; fainting spells; meningitis Stage 3: fluid buildup in joints; neuropathy How you can prevent, treat Lyme disease The New Jersey Department of Health advises you to avoid wooded areas with dense shrubs and leaf litter, wearing protective clothing, using insect repellents, perform tick checks and mowing lawns frequently will help you avoid tick bites and Lyme disease. "After spending time in tick-infested areas, ask a partner to check you for ticks in areas on your body that you can't see very well," advised the Harvard Medical School. "The common bite areas are the back of the knee, the groin, under the arms, under the breasts in women, behind the ears, and at the back of the neck." Justin Timberlake confirms Lyme disease diagnosis Superstar pop singer Justin Timberlake told his fans in an instagram post that his Lyme disease diagnosis nearly forced him off tour. "Among other things, I've been battling some health issues, and was diagnosed with Lyme disease - which I don't say so you feel bad for me - but to shed some light on what I've been up against behind the scenes," read a portion of Timberlake's lengthy Instagram post. "If you've experienced this disease or know someone who has, then you're aware: living with this can be relentlessly debilitating, both mentally and physically. "When I first got the diagnosis I was shocked for sure. But, at least I could understand why I would be onstage and in a massive amount of nerve pain or, just feeling crazy fatigue or sickness," Timberlake's post continued. "I was faced with a personal decision. Stop touring? Or, keep going and figure it out. I decided the joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going." According to Business Insider, Timberlake is just the most recent celebrity to come down with Lyme disease. In 2020, both Justin Bieber and Amy Schumer reportedly confirmed their Lyme disease diagnosis, and Avril Lavigne was reportedly bedridden by Lyme disease in 2014. Damon C. Williams is a Philadelphia-based journalist reporting on trending topics across the Mid-Atlantic Region. This article originally appeared on What is Lyme disease, and did Justin Timberlake say he had it? Solve the daily Crossword